 This single-center study will enroll a maximum of 40 patients with LDL-C 100 and A1c values between 6.5-9, who will be randomized in a 1:1 fashion to either the study drug or placebo. Visits will be conducted at screening, baseline, one month, two months, and three months. At home, subjects will take 3.75 gmsday of colesevelam HCl or placebo throughout the study duration. Laboratory analysis will be performed at various timepoints assessing A1c, fasting lipid panel, c-peptide, glucagon-like-peptide-1 GLP-1, and glucose-dependent insulinotropic peptide GIP. Continuous glucose monitoring CGM measurements will be obtained on all patients for one week before each monthly visit to assess for above target range ATR, within target range WTR, and below target range BTR glucose values and time spent in hyperglycemic and hypoglycemic excursions. 